INAB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 33.00%

Insider Buying (Last 12 Months): $28,395.00

Insider Selling (Last 12 Months): $0.00

IN8bio Insider Trading History Chart

IN8bio Share Price & Price History

^$1.04

▼ -0.01 (-0.95%)

As of 04/19/2024 03:43 PM ET

Days: 30 | 90 | 365

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

IN8bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/13/2023	Jeremy R Graff	Director	Buy	2,500	$0.95	$2,375.00	2,500
8/25/2023	Patrick Mccall	CFO	Buy	1,000	$1.03	$1,030.00	6,263
8/24/2023	William Tai-Wei Ho	CEO	Buy	23,800	$1.05	$24,990.00	2,339,545
8/16/2022	Emily Fairbairn	Director	Buy	789,473	$1.90	$1,499,998.70	4,111,958
8/16/2022	Kate Rochlin	COO	Buy	5,263	$1.90	$9,999.70	5,263
8/16/2022	Lawrence Lamb	EVP	Buy	526	$1.90	$999.40	99,730
8/16/2022	Trishna Goswami	Insider	Buy	2,631	$1.90	$4,998.90	2,631
8/16/2022	William Tai-Wei Ho	CEO	Buy	26,315	$1.90	$49,998.50	2,315,745

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

SEC Filings (Institutional Ownership Changes) for IN8bio (NASDAQ:INAB)

92.05% of IN8bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

IN8bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/11/2024	Vanguard Group Inc.	416,696	$0.58M	0.0%	+23.0%	1.303%
2/15/2024	Vanguard Group Inc.	416,696	$0.58M	0.0%	+23.0%	1.303%
2/15/2024	Citadel Advisors LLC	19,807	$27K	0.0%	N/A	0.062%
2/12/2024	AIGH Capital Management LLC	4,098,361	$5.22M	2.1%	N/A	12.811%
2/8/2024	Texas Capital Bank Wealth Management Services Inc	78,624	$0.11M	0.0%	+85.2%	0.246%
2/1/2024	Sigma Planning Corp	132,230	$0.18M	0.0%	-53.6%	0.413%
1/30/2024	Voss Capital LLC	341,209	$0.47M	0.0%	-33.3%	1.067%
12/18/2023	Vanguard Group Inc.	338,728	$0.35M	0.0%	+17.8%	1.059%
11/13/2023	Rock Creek Group LP	151,314	$0.16M	0.0%	+98.3%	0.473%
10/19/2023	Voss Capital LLC	511,584	$0.53M	0.1%	+11.7%	1.619%
8/15/2023	Citadel Advisors LLC	57,722	$89K	0.0%	N/A	0.183%
8/14/2023	State Street Corp	59,246	$91K	0.0%	N/A	0.187%
8/11/2023	Overbrook Management Corp	33,756	$52K	0.0%	N/A	0.113%
8/11/2023	Renaissance Technologies LLC	21,700	$33K	0.0%	N/A	0.073%
8/11/2023	BlackRock Inc.	45,091	$69K	0.0%	+38.3%	0.152%
8/11/2023	Geode Capital Management LLC	176,561	$0.27M	0.0%	+205.2%	0.593%
8/11/2023	Northern Trust Corp	43,258	$67K	0.0%	+226.4%	0.145%
8/2/2023	Sigma Planning Corp	279,400	$0.43M	0.0%	+37.0%	0.939%
7/28/2023	Voss Capital LLC	457,876	$0.71M	0.1%	+35.5%	1.539%
5/12/2023	Dimensional Fund Advisors LP	24,482	$32K	0.0%	+119.5%	0.098%
5/8/2023	Sigma Planning Corp	203,900	$0.27M	0.0%	+105.6%	0.816%
2/13/2023	Voss Capital LLC	338,019	$0.78M	0.2%	-10.0%	1.380%
2/13/2023	Geode Capital Management LLC	58,665	$0.14M	0.0%	+12.1%	0.239%
2/9/2023	Dimensional Fund Advisors LP	11,153	$26K	0.0%	N/A	0.046%
11/15/2022	Vanguard Group Inc.	169,528	$0.34M	0.0%	+53.1%	0.692%
11/15/2022	Precept Management LLC	50,000	$0.10M	0.7%	N/A	0.204%
11/7/2022	Warberg Asset Management LLC	15,000	$30K	0.0%	N/A	0.080%
11/2/2022	Voss Capital LLC	375,570	$0.76M	0.2%	-25.7%	1.993%
10/28/2022	Stonegate Investment Group LLC	232,310	$0.47M	0.0%	-12.8%	1.233%
10/24/2022	United Asset Strategies Inc.	14,000	$28K	0.0%	N/A	0.074%
8/15/2022	Nantahala Capital Management LLC	148,801	$0.36M	0.0%	-57.8%	0.790%
8/13/2022	Voss Capital LLC	505,635	$1.14M	0.4%	+95.2%	2.684%
8/9/2022	Stonegate Investment Group LLC	266,500	$0.60M	0.0%	N/A	1.415%
5/13/2022	Nantahala Capital Management LLC	352,753	$1.23M	0.1%	-5.5%	1.875%
5/13/2022	Vanguard Group Inc.	111,493	$0.37M	0.0%	-7.3%	0.593%
5/12/2022	BlackRock Inc.	16,334	$54K	0.0%	+70.8%	0.087%
5/11/2022	Rock Creek Group LP	86,032	$0.30M	0.0%	+87.5%	0.457%
4/20/2022	Sigma Planning Corp	97,750	$0.33M	0.0%	+241.8%	0.520%
2/11/2022	Ensign Peak Advisors Inc	70,028	$0.31M	0.0%	N/A	0.373%
2/10/2022	HighTower Advisors LLC	10,000	$44K	0.0%	N/A	0.053%
2/2/2022	Sigma Planning Corp	28,600	$0.13M	0.0%	N/A	0.153%
11/16/2021	Voss Capital LLC	80,727	$0.56M	0.2%	N/A	0.430%
11/16/2021	Capital World Investors	800,000	$5.52M	0.0%	N/A	4.266%
11/15/2021	Tudor Investment Corp Et Al	63,287	$0.43M	0.0%	N/A	0.337%
11/10/2021	B. Riley Financial Inc.	257,378	$1.76M	0.2%	N/A	1.372%

Data available starting January 2016

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Today's Range

Now: $1.04

$0.99

$1.09

50 Day Range

MA: $1.14

$0.95

$1.30

52 Week Range

Now: $1.04

$0.65

$3.95

Volume

250,901 shs

Average Volume

318,214 shs

Market Capitalization

$33.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of IN8bio?: IN8bio's top insider shareholders include:
Emily Fairbairn (Director)
William Tai-Wei Ho (CEO)
Lawrence Lamb (EVP)
Patrick Mccall (CFO)
Kate Rochlin (COO)
Trishna Goswami (Insider)
Jeremy R Graff (Director)
Learn More about top insider investors at IN8bio.